Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at Oxford’s Nuffield Department of Surgical Sciences (NDS) have developed a nerve implant that continually releases minute quantities of a drug that stops scarring.

Construction of steroid eluting microchannel implants (end view).  (a) The seven layers that make up the channel array. (b) Assembled channel array. (c) Close-up of part of panel (b) showing details of channel and drug layer dimensions. © James FitzGerald
Construction of steroid eluting microchannel implants (end view). (a) The seven layers that make up the channel array. (b) Assembled channel array. (c) Close-up of part of panel (b) showing details of channel and drug layer dimensions.

Neural interfaces are medical devices that are designed to be surgically implanted into nerves after an amputation, to allow signals to be extracted from the nervous system in order to control artificial limbs. Several types of interface implant have been developed but none has reached clinical use yet, because although they may work well initially, they gradually cease to function because of the development of scarring around them, which until now could not be prevented. 

'Scarring is a natural response of the body to artificial material, and happens around almost all types of implanted medical devices' said Dr James FitzGerald, a consultant neurosurgeon at NDS who led the study. 'It is a particular problem for nerve interfaces where the scar tissue gets in between nerve fibres and electrodes and pushes them apart, reducing signal strength. In some types of implant the scar tissue can actually strangulate the nerve fibres'. 

Solving the scarring problem is a key requirement for long term function of nerve interfaces. - Dr James FitzGerald

The researchers constructed nerve implants containing tiny quantities of a steroid drug called dexamethasone. Tests showed drug release was sustained over a one year period and resulted in a dramatic reduction in scarring. The amount of drug released per day was equivalent to less than one thousandth of the body’s normal daily production of steroids. The challenge now will be to develop the technology to the point where drug release can be sustained for even longer periods.

Dr FitzGerald said: 'Solving the scarring problem is a key requirement for long term function of nerve interfaces. Drug elution allows scar suppression in the immediate vicinity of the implant using tiny quantities of drug that should have no side effects. Now we need to extend the period of anti-scarring protection, eventually to decades'.

The research is published in the Journal of Neural Engineering.

Similar stories

New Cochrane evidence explores treatment options for chronic ear disease

Publication Research

A new Evidently Cochrane blog post for World Hearing Day summarises seven recent reviews on medical treatments for infection and inflammation of the middle ear.

New reporting guidelines to bridge the gap from development to implementation in clinical artificial intelligence

Innovation Research

In a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.

Cochrane ENT awarded NIHR funding for COVID-19 project

Awards and appointments Coronavirus COVID-19 Research

Cochrane ENT at the Nuffield Department of Surgical Sciences has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection.

JNDS: new issue out now

Department Publication

Journal of the Nuffield Department of Surgical Sciences (JNDS) has published its next issue, featuring top case reports written by University of Oxford medical students during their clinical studies.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

Coronavirus COVID-19 Publication Research

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Applications for Oxford-Wolfson-Marriott-Patel Scholarship now open

Awards and appointments Department Research

The Nuffield Department of Surgical Sciences (NDS) are pleased to confirm that one scholarship will be available for Home (UK) and Republic of Ireland (ROI) candidates for the DPhil in Surgical Sciences, starting in Michaelmas Term 2021.